Symbols / SNDX
SNDX Chart
About
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.78B |
| Enterprise Value | 1.68B | Income | -311.58M | Sales | 111.30M |
| Book/sh | 1.33 | Cash/sh | 5.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 270 | IPO | — |
| P/E | — | Forward P/E | -13.34 | PEG | — |
| P/S | 16.03 | P/B | 15.46 | P/C | — |
| EV/EBITDA | -5.46 | EV/Sales | 15.05 | Quick Ratio | 4.36 |
| Current Ratio | 4.64 | Debt/Eq | 299.26 | LT Debt/Eq | — |
| EPS (ttm) | -3.60 | EPS next Y | -1.54 | EPS Growth | — |
| Revenue Growth | 267.00% | Earnings | 2026-02-26 | ROA | -39.24% |
| ROE | -129.32% | ROIC | — | Gross Margin | -119.70% |
| Oper. Margin | -125.19% | Profit Margin | -279.93% | Shs Outstand | 86.91M |
| Shs Float | 73.40M | Short Float | 27.45% | Short Ratio | 16.17 |
| Short Interest | — | 52W High | 22.73 | 52W Low | 8.58 |
| Beta | 0.44 | Avg Volume | 1.46M | Volume | 633.05K |
| Target Price | $38.92 | Recom | Strong_buy | Prev Close | $19.90 |
| Price | $20.53 | Change | 3.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.92
Mean price target
2. Current target
$20.53
Latest analyst target
3. DCF / Fair value
$-40.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$20.53
Low
$27.00
High
$56.00
Mean
$38.92
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | Mizuho | Outperform → Outperform | $600 |
| 2025-12-09 | reit | BTIG | Buy → Buy | $56 |
| 2025-11-24 | main | Barclays | Overweight → Overweight | $35 |
| 2025-11-12 | main | JP Morgan | Overweight → Overweight | $33 |
| 2025-11-04 | main | UBS | Buy → Buy | $38 |
| 2025-11-04 | main | Barclays | Overweight → Overweight | $22 |
| 2025-10-27 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-27 | reit | BTIG | Buy → Buy | $56 |
| 2025-09-19 | reit | BTIG | Buy → Buy | $56 |
| 2025-09-05 | main | Goldman Sachs | Buy → Buy | $24 |
| 2025-09-04 | init | Guggenheim | — → Buy | $34 |
| 2025-08-05 | main | Citigroup | Buy → Buy | $51 |
| 2025-08-05 | main | BTIG | Buy → Buy | $56 |
| 2025-07-15 | main | UBS | Buy → Buy | $35 |
| 2025-07-10 | init | Goldman Sachs | — → Buy | $18 |
| 2025-05-06 | main | Scotiabank | Sector Perform → Sector Perform | $17 |
| 2025-05-06 | reit | Guggenheim | Buy → Buy | $32 |
| 2025-03-20 | main | JP Morgan | Overweight → Overweight | $41 |
| 2025-03-04 | main | JP Morgan | Overweight → Overweight | $39 |
| 2025-03-04 | main | Citigroup | Buy → Buy | $42 |
- Biotech CEO plans three March investor Q&As in Boston and Miami - Stock Titan Mon, 23 Feb 2026 12
- Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday - MarketBeat Mon, 23 Feb 2026 09
- Syndax to Announce Fourth Quarter and Full Year 2025 - GlobeNewswire hu, 19 Feb 2026 12
- Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha hu, 12 Feb 2026 08
- Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock - Investing.com Fri, 06 Feb 2026 08
- Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: A 150% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews Fri, 17 Oct 2025 07
- Is Syndax Pharmaceuticals (SNDX) Pricing Reflecting Recent Biotech Reassessment Or Long Term Potential - Yahoo Finance Sun, 15 Feb 2026 08
- Insider Sale: Chief Executive Officer of $SNDX Sells 7,412 Shares - Quiver Quantitative Fri, 06 Feb 2026 08
- Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up - simplywall.st Sun, 23 Nov 2025 08
- Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat Sat, 21 Feb 2026 08
- Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance Mon, 16 Feb 2026 08
- Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha Sat, 29 Nov 2025 08
- Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After A 46% One Year Share Price Gain? - simplywall.st hu, 12 Feb 2026 08
- Keith Goldan Sells 3,410 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat ue, 10 Feb 2026 08
- Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX) - Seeking Alpha Wed, 17 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3410 | 71705 | — | Sale at price 21.03 per share. | GOLDAN KEITH ALAN | Chief Financial Officer | — | 2026-02-09 00:00:00 | D |
| 1 | 17159 | 360819 | — | Sale at price 21.03 per share. | METZGER MICHAEL A | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 2 | 2082 | 42931 | — | Sale at price 20.62 per share. | GOLDAN KEITH ALAN | Chief Financial Officer | — | 2026-02-06 00:00:00 | D |
| 3 | 7412 | 152835 | — | Sale at price 20.62 per share. | METZGER MICHAEL A | Chief Executive Officer | — | 2026-02-06 00:00:00 | D |
| 4 | 48000 | — | — | Stock Award(Grant) at price 0.00 per share. | PODLESAK DENNIS G | Director | — | 2026-02-04 00:00:00 | D |
| 5 | 24000 | — | — | Stock Award(Grant) at price 0.00 per share. | KATKIN KEITH A | Director | — | 2026-02-04 00:00:00 | D |
| 6 | 24000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEGAULT PIERRE | Director | — | 2026-02-04 00:00:00 | D |
| 7 | 52250 | — | — | Stock Award(Grant) at price 0.00 per share. | GOLDAN KEITH ALAN | Chief Financial Officer | — | 2026-02-04 00:00:00 | D |
| 8 | 217600 | — | — | Stock Award(Grant) at price 0.00 per share. | METZGER MICHAEL A | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 9 | 24000 | — | — | Stock Award(Grant) at price 0.00 per share. | HUBER MARTIN H JR | Director | — | 2026-02-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -313.82M | -209.14M | -146.17M | 26.87M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -318.76M | -209.36M | -149.34M | 24.93M |
| ReconciledDepreciation | 8.00K | 12.00K | 33.00K | 43.00K |
| ReconciledCostOfRevenue | 826.00K | 0.00 | 0.00 | |
| EBITDA | -313.82M | -209.14M | -146.17M | 26.87M |
| EBIT | -313.83M | -209.15M | -146.20M | 26.82M |
| NetInterestIncome | 21.16M | 20.95M | 2.73M | -1.50M |
| InterestExpense | 4.93M | 208.00K | 3.14M | 1.90M |
| InterestIncome | 26.09M | 21.16M | 5.87M | 403.00K |
| NormalizedIncome | -318.76M | -209.36M | -149.34M | 24.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -318.76M | -209.36M | -149.34M | 24.93M |
| TotalExpenses | 363.35M | 229.95M | 151.76M | 113.49M |
| TotalOperatingIncomeAsReported | -339.67M | -229.95M | -151.76M | 26.22M |
| DilutedAverageShares | 85.62M | 70.37M | 60.76M | 52.06M |
| BasicAverageShares | 85.62M | 70.37M | 60.76M | 52.06M |
| DilutedEPS | -3.72 | -2.98 | -2.46 | 0.48 |
| BasicEPS | -3.72 | -2.98 | -2.46 | 0.48 |
| DilutedNIAvailtoComStockholders | -318.76M | -209.36M | -149.34M | 24.93M |
| NetIncomeCommonStockholders | -318.76M | -209.36M | -149.34M | 24.93M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | ||
| NetIncome | -318.76M | -209.36M | -149.34M | 24.93M |
| NetIncomeIncludingNoncontrollingInterests | -318.76M | -209.36M | -149.34M | 24.93M |
| NetIncomeContinuousOperations | -318.76M | -209.36M | -149.34M | 24.93M |
| PretaxIncome | -318.76M | -209.36M | -149.34M | 24.93M |
| OtherIncomeExpense | -247.00K | -361.00K | -316.00K | 202.00K |
| OtherNonOperatingIncomeExpenses | -247.00K | -361.00K | -316.00K | 202.00K |
| NetNonOperatingInterestIncomeExpense | 21.16M | 20.95M | 2.73M | -1.50M |
| InterestExpenseNonOperating | 4.93M | 208.00K | 3.14M | 1.90M |
| InterestIncomeNonOperating | 26.09M | 21.16M | 5.87M | 403.00K |
| OperatingIncome | -339.67M | -229.95M | -151.76M | 26.22M |
| OperatingExpense | 362.53M | 229.95M | 151.76M | 113.49M |
| ResearchAndDevelopment | 241.65M | 163.03M | 118.50M | 88.25M |
| SellingGeneralAndAdministration | 120.88M | 66.92M | 33.26M | 25.24M |
| GeneralAndAdministrativeExpense | 120.88M | 66.92M | 33.26M | 25.24M |
| OtherGandA | 50.89M | 27.22M | 33.26M | 25.24M |
| SalariesAndWages | 69.98M | 39.70M | ||
| GrossProfit | 22.85M | 0.00 | 0.00 | |
| CostOfRevenue | 826.00K | 0.00 | 0.00 | |
| TotalRevenue | 23.68M | 0.00 | 0.00 | 139.71M |
| OperatingRevenue | 23.68M | 0.00 | 0.00 | 139.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 85.69M | 84.83M | 68.11M | 54.98M |
| ShareIssued | 85.69M | 84.83M | 68.11M | 54.98M |
| NetDebt | 189.60M | |||
| TotalDebt | 345.74M | 1.64M | 1.16M | 20.97M |
| TangibleBookValue | 288.12M | 554.20M | 467.45M | 408.37M |
| InvestedCapital | 631.80M | 554.20M | 467.45M | 428.26M |
| WorkingCapital | 499.51M | 522.78M | 460.72M | 427.71M |
| NetTangibleAssets | 288.12M | 554.20M | 467.45M | 408.37M |
| CapitalLeaseObligations | 2.06M | 1.64M | 1.16M | 1.07M |
| CommonStockEquity | 288.12M | 554.20M | 467.45M | 408.37M |
| TotalCapitalization | 619.69M | 554.20M | 467.45M | 428.26M |
| TotalEquityGrossMinorityInterest | 288.12M | 554.20M | 467.45M | 408.37M |
| StockholdersEquity | 288.12M | 554.20M | 467.45M | 408.37M |
| GainsLossesNotAffectingRetainedEarnings | 163.00K | 218.00K | -806.00K | 45.00K |
| OtherEquityAdjustments | 163.00K | 218.00K | -806.00K | 45.00K |
| RetainedEarnings | -1.22B | -902.40M | -693.04M | -543.70M |
| AdditionalPaidInCapital | 1.51B | 1.46B | 1.16B | 952.02M |
| CapitalStock | 9.00K | 8.00K | 7.00K | 6.00K |
| CommonStock | 9.00K | 8.00K | 7.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 436.69M | 58.68M | 29.79M | 41.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 333.14M | 588.00K | 722.00K | 20.61M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 333.14M | 588.00K | 722.00K | 20.61M |
| LongTermCapitalLeaseObligation | 1.58M | 588.00K | 722.00K | 711.00K |
| LongTermDebt | 331.56M | 19.89M | ||
| CurrentLiabilities | 103.55M | 58.10M | 29.07M | 20.68M |
| OtherCurrentLiabilities | 1.27M | 888.00K | 604.00K | 1.89M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 12.60M | 1.05M | 439.00K | 362.00K |
| CurrentCapitalLeaseObligation | 480.00K | 1.05M | 439.00K | 362.00K |
| CurrentDebt | 12.12M | |||
| OtherCurrentBorrowings | 12.12M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 14.48M | 11.17M | 5.95M | 4.34M |
| PayablesAndAccruedExpenses | 75.21M | 44.99M | 22.08M | 14.09M |
| CurrentAccruedExpenses | 44.04M | 27.80M | 17.73M | 8.42M |
| InterestPayable | 4.93M | 0.00 | ||
| Payables | 31.16M | 17.19M | 4.35M | 5.67M |
| OtherPayable | 19.54M | 7.23M | ||
| AccountsPayable | 11.63M | 9.96M | 4.35M | 5.67M |
| TotalAssets | 724.82M | 612.88M | 497.24M | 449.66M |
| TotalNonCurrentAssets | 121.76M | 32.00M | 7.45M | 1.26M |
| OtherNonCurrentAssets | 217.00K | 680.00K | 922.00K | |
| InvestmentsAndAdvances | 119.52M | 29.83M | 5.47M | 0.00 |
| InvestmentinFinancialAssets | 119.52M | 29.83M | ||
| AvailableForSaleSecurities | 119.52M | 29.83M | ||
| NetPPE | 2.02M | 1.50M | 1.06M | 1.26M |
| AccumulatedDepreciation | -419.00K | -411.00K | -399.00K | -443.00K |
| GrossPPE | 2.44M | 1.91M | 1.46M | 1.70M |
| Leases | 167.00K | 167.00K | 167.00K | 167.00K |
| OtherProperties | 2.11M | 1.57M | 1.12M | 1.37M |
| MachineryFurnitureEquipment | 168.00K | 168.00K | 168.00K | 168.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 603.06M | 580.88M | 489.79M | 448.40M |
| OtherCurrentAssets | 612.00K | 63.00K | 117.00K | 150.00K |
| RestrictedCash | 0.00 | 115.00K | ||
| PrepaidAssets | 5.29M | 2.00M | 1.22M | 872.00K |
| Inventory | 366.00K | 0.00 | ||
| FinishedGoods | 36.00K | 0.00 | ||
| WorkInProcess | 330.00K | 0.00 | ||
| RawMaterials | 0.00 | 0.00 | ||
| Receivables | 13.87M | 1.23M | 4.06M | 429.00K |
| OtherReceivables | 3.63M | |||
| AccruedInterestReceivable | 2.63M | 1.23M | 583.00K | 429.00K |
| NotesReceivable | 3.47M | 0.00 | ||
| AccountsReceivable | 7.60M | 0.00 | 3.47M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 582.91M | 577.58M | 484.40M | 446.83M |
| OtherShortTermInvestments | 428.83M | 282.19M | 410.04M | 224.87M |
| CashAndCashEquivalents | 154.08M | 295.39M | 74.36M | 221.97M |
| CashEquivalents | 154.08M | 295.39M | 74.36M | 221.97M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -274.90M | -160.60M | -133.68M | 29.00M |
| RepaymentOfDebt | 0.00 | 0.00 | -21.00M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 258.09M | 181.39M | 86.34M |
| CapitalExpenditure | -129.00K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 2.06M | 2.00M |
| EndCashPosition | 154.30M | 295.61M | 74.47M | 222.08M |
| BeginningCashPosition | 295.61M | 74.47M | 222.08M | 115.36M |
| ChangesInCash | -141.31M | 221.14M | -147.61M | 106.72M |
| FinancingCashFlow | 353.37M | 264.13M | 172.25M | 118.46M |
| CashFlowFromContinuingFinancingActivities | 353.37M | 264.13M | 172.25M | 118.46M |
| NetOtherFinancingCharges | 343.65M | 576.00K | ||
| ProceedsFromStockOptionExercised | 9.71M | 6.04M | 11.86M | 31.55M |
| NetCommonStockIssuance | 0.00 | 258.09M | 181.39M | 86.34M |
| CommonStockIssuance | 0.00 | 258.09M | 181.39M | 86.34M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -21.00M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -21.00M | 0.00 |
| LongTermDebtPayments | 0.00 | 0.00 | -21.00M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -219.78M | 117.61M | -186.19M | -40.87M |
| CashFlowFromContinuingInvestingActivities | -219.78M | 117.61M | -186.19M | -40.87M |
| NetInvestmentPurchaseAndSale | -219.78M | 117.61M | -186.41M | -40.74M |
| SaleOfInvestment | 337.28M | 472.21M | 308.93M | 253.97M |
| PurchaseOfInvestment | -557.05M | -354.61M | -495.35M | -294.72M |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | 225.00K | -129.00K |
| SaleOfPPE | 0.00 | 0.00 | 225.00K | 0.00 |
| PurchaseOfPPE | 0.00 | 0.00 | -129.00K | |
| OperatingCashFlow | -274.90M | -160.60M | -133.68M | 29.13M |
| CashFlowFromContinuingOperatingActivities | -274.90M | -160.60M | -133.68M | 29.13M |
| ChangeInWorkingCapital | 13.27M | 31.86M | 1.66M | -9.60M |
| ChangeInOtherWorkingCapital | 12.00M | 10.71M | -3.47M | -13.13M |
| ChangeInOtherCurrentAssets | 463.00K | 0.00 | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 20.80M | 20.48M | 8.10M | 4.93M |
| ChangeInAccruedExpense | 19.14M | 14.87M | 9.42M | 2.77M |
| ChangeInPayable | 1.67M | 5.61M | -1.32M | 2.16M |
| ChangeInAccountPayable | 1.67M | 5.61M | -1.32M | 2.16M |
| ChangeInPrepaidAssets | -8.39M | 676.00K | -2.97M | -1.39M |
| ChangeInInventory | -366.00K | 0.00 | 0.00 | |
| ChangeInReceivables | -11.24M | 0.00 | 0.00 | 0.00 |
| ChangesInAccountReceivables | -7.60M | 0.00 | 0.00 | |
| OtherNonCashItems | 1.02M | 739.00K | 1.52M | 187.00K |
| StockBasedCompensation | 43.03M | 30.95M | 16.02M | 13.32M |
| AmortizationOfSecurities | -13.47M | -14.80M | -3.38M | 644.00K |
| DepreciationAmortizationDepletion | 8.00K | 12.00K | 33.00K | 43.00K |
| DepreciationAndAmortization | 8.00K | 12.00K | 33.00K | 43.00K |
| Depreciation | 8.00K | 12.00K | 33.00K | 43.00K |
| OperatingGainsLosses | -187.00K | -389.00K | ||
| GainLossOnInvestmentSecurities | -187.00K | -389.00K | ||
| NetIncomeFromContinuingOperations | -318.76M | -209.36M | -149.34M | 24.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SNDX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|